DOCSLIB.ORG

Action to Strengthen the 2030 Agenda for Sustainable Development

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Action to Strengthen the 2030 Agenda for Sustainable Development Building forward better Action to strengthen the 2030 Agenda for Sustainable Development Fourth report on regional progress and challenges in relation to the 2030 Agenda for Sustainable Development in Latin America and the Caribbean Forum of the Countries of Latin America and the Caribbean on SUSTAINABLE DEVELOPMENT Virtual meeting 15 – 18 March 2021 Thank you for your interest in this ECLAC publication ECLAC Publications Please register if you would like to receive information on our editorial products and activities. When you register, you may specify your particular areas of interest and you will gain access to our products in other formats. www.cepal.org/en/publications ublicaciones www.cepal.org/apps Alicia Bárcena Executive Secretary Mario Cimoli Deputy Executive Secretary Raúl García-Buchaca Deputy Executive Secretary for Management and Programme Analysis Sally Shaw Officer-in-Charge of the Documents and Publications Division Work on this document was coordinated by Alicia Bárcena, Executive Secretary of the Economic Commission for Latin America and the Caribbean (ECLAC), with the collaboration of Mario Cimoli, Deputy Executive Secretary, and Luis Yáñez, Secretary of the Commission. The drafting committee comprised Wilson Peres, Gabriel Porcile, Daniel Taccari and Zebulun Kreiter, with the collaboration of Romain Zivy, Vianka Aliaga, Vera Kiss and María Ortiz, all of ECLAC. The following chiefs of ECLAC substantive divisions, subregional headquarters and country offices participated in the preparation of this document: Daniel Titelman, Chief of the Economic Development Division; Rolando Ocampo, Chief of the Statistics Division; Simone Cecchini, Officer-in-Charge of the Social Development Division; Paulo Saad; Chief of the Latin American and Caribbean Demographic Centre (CELADE)-Population Division of ECLAC; Cielo Morales, Chief of the Latin American and Caribbean Institute for Economic and Social Planning (ILPES); Giovanni Stumpo, Officer-in-Charge of the Division of Production, Productivity and Management; Joseluis Samaniego, Chief of the Sustainable Development and Human Settlements Division; Jeannette Sánchez, Chief of the Natural Resources Division; Ana Güezmes, Chief of the Division for Gender Affairs; Mario Castillo, Chief of the Division of International Trade and Integration; Miguel Torres, Editor of the CEPAL Review; Hugo Beteta, Chief of the ECLAC subregional headquarters in Mexico; Diane Quarless, Chief of the ECLAC subregional headquarters for the Caribbean; Gabriel Porcile, Chief of the ECLAC office in Montevideo; Martín Abeles, Chief of the ECLAC office in Buenos Aires; Olga Lucía Acosta, Officer-in-Charge of the ECLAC office in Bogotá; Carlos Mussi, Chief of the ECLAC office in Brasilia; and Inés Bustillo, Chief of the ECLAC office in Washington, D.C. The authors are particularly grateful for the collaboration of the following staff members of ECLAC: Abdullahi Abdulkadri, Mónica Aguayo, José Eduardo Alatorre, Dillon Alleyne, Dante Arenas, Bernardo Atuesta, Diego Aulestia, Guiomar Bay, Amelia Bleeker, Alejandro Bustamante, Catarina Camarinhas, Georgina Cipoletta, Rubén Contreras, Helena Cruz Castanheira, Carlos de Miguel, Fabiana Del Popolo, Artie Dubrie, Mareike Eberz, Ernesto Espíndola, Álvaro Fuentes, Lydia Gény, Nicolo Gligo, Candice Gonzales, Camila Gramkow, Michael Hanni, Sebastián Herreros, Francis Jones, Alberto Malmierca, Xavier Mancero, Sandra Manuelito, Karina Martínez, Rodrigo Martínez, Sheldon McLean, Beatriz Morales, Enrique Oviedo, Machel Pantin, Esteban Pérez, Noel Pérez, Willard Phillips, Ramón Pineda, Laura Poveda, Claudia Robles, Mónica Rodrigues, Adrián Rodríguez, Jorge Rodríguez, Sebastián Rovira, Lucía Scuro, Zulma Sosa, Pauline Stockins, Valeria Torres, Marcia Tambutti, Daniela Trucco, Iliana Vaca Trigo, Helvia Velloso, Cecilia Vera, Francisco Villarreal, Lucy Winchester and Sheng Zhao. The following ECLAC consultants also provided input for the preparation of the document: Tarek Abdo, Raúl Holz, Nicolás Grinblatt, Carlos Pérez Verdía and Alynn Sánchez. The boundaries and names shown on the maps included in this publication do not imply official endorsement or acceptance by the United Nations. Explanatory notes - Three dots (…) indicate that data are missing, are not available or are not separately reported. - A dash (-) indicates that the amount is nil or negligible. - A full stop (.) is used to indicate decimals. - The word “dollars” refers to United States dollars unless otherwise specified. - A slash (/) between years (e.g. 2013/2014) indicates a 12-month period falling between the two years. - Individual figures and percentages in tables may not always add up to the corresponding total due to rounding. United Nations publication LC/FDS.4/3/Rev.1 Distribution: G Copyright © United Nations, 2021 All rights reserved Printed at United Nations, Santiago S.21-00124 This publication should be cited as: Economic Commission for Latin America and the Caribbean (ECLAC), Building forward better: action to strengthen the 2030 Agenda for Sustainable Development (LC/FDS.4/3/Rev.1), Santiago, 2021. Applications for authorization to reproduce this work in whole or in part should be sent to the Economic Commission for Latin America and the Caribbean (ECLAC), Documents and Publications Division, [email protected]. Member States and their governmental institutions may reproduce this work without prior authorization, but are requested to mention the source and to inform ECLAC of such reproduction. Contents Foreword ............................................................................................................................................................................................................9 CHAPTER I Latin America and the Caribbean before the outbreak of COVID-19 ....................................................................................................11 Introduction ..................................................................................................................................................................................................13 A. A halting recovery from the 2008 crisis: the limits of monetary policy and debt ................................................................................13 B. Inequality as a barrier to global recovery and stability ........................................................................................................................16 C. The climate and environmental emergency ..........................................................................................................................................18 D. The crisis of multilateralism and the need for developing economies to speak with one voice .........................................................23 E. Concluding observations .......................................................................................................................................................................25 Bibliography ..................................................................................................................................................................................................26 CHAPTER II The worst health crisis in over a century ...................................................................................................................................................27 A. The region in times of pandemic...........................................................................................................................................................29 B. Effects on life expectancy .....................................................................................................................................................................31 C. Risk factors ............................................................................................................................................................................................33 D. Weak, fragmented and unequal health systems ..................................................................................................................................38 1. Working women are on the front line of care ................................................................................................................................39 2. Reduction in women’s sexual and reproductive health services ...................................................................................................40 E. Policy responses ....................................................................................................................................................................................41 1. Physical distancing .........................................................................................................................................................................41 2. Strengthening health systems........................................................................................................................................................41 3. Vaccination progress ......................................................................................................................................................................43 Bibliography ..................................................................................................................................................................................................47 CHAPTER III The economic, social and environmental
Load more

Recommended publications
  • Supplemental Statement
    Received by NSD/FARA Registration Unit 06/21/2021 2:43:26 PM OMB No. 1124-0002; Expires July 31, 2023 U.S. Department of Justice Supplemental Statement Washington, dc 20530 Pursuant to the Foreign Agents Registration Act of 1938, as amended For 6 Month Period Ending May 31, 2021 (Insert dale) I - REGISTRANT 1. (a) Name of Registrant (b) Registration Number Reston Translator, LLC 6490 (c) Primary Business Address On file with DOJ 2. Has there been a change in the information previously furnished in connection with the following? (a) If an individual: (1) Residence address(es) Yes □ No □ (2) Citizenship Yes □ No □ (3) Occupation Yes □ No □ (b) If an organization: (1) Name Yes □ No 0 (2) Ownership or control Yes □ No 0 (3) Branch offices Yes □ No 0 (c) Explain fully all changes, if any, indicated in Items (a) and (b) above. IF THE REGISTRANT IS AN INDIVIDUAL, OMIT RESPONSES TO ITEMS 3, 4, 5, AND 6. 3. If the registrant previously filed an Exhibit C*1, state whether any changes therein have occurred during this 6 month reporting period. Yes □ No 0 If yes, has the registrant filed an updated Exhibit C? Yes □ No □ If no, please file the updated Exhibit C. 1 The Exhibit C, for which no printed form is provided, consists of a true copy of the charter, articles of incorporation, association, and by laws of a registrant that is an organization. (A waiver of the requirement to file an Exhibit C may be obtained for good cause upon written application to the Assistant Attorney General, National Security Division, U.S.
    [Show full text]
  • New Brunswick COVID-19 Vaccine Clinic Guide for Immunizers
    New Brunswick COVID-19 Vaccine Clinic Guide for Immunizers Department of Health Public Health New Brunswick September 17, 2021 Public Health New Brunswick New Brunswick Department of Health PO Box 5100 Fredericton, New Brunswick, E3B 5G8 Canada This report is available online: www.gnb.ca/publichealth Ce document est aussi disponible en français sur le titre «Guide sur la vaccination contre la COVID-19 pour les Vaccinateurs du Nouveau-Brunswick ». TABLE OF CONTENTS NEW BRUNSWICK COVID-19 CLINIC GUIDE FOR IMMUNIZERS .......................................................... 1 1.0. PURPOSE ....................................................................................................................................... 1 2.0. VACCINE SOP ON TRANSPORTATION AND RECEIPT ............................................................. 1 Vaccines – storage and handling and maintaining cold chain to prevent temperature excursions (portable freezers and refrigeration) .......................................................... 2 3.0. SCHEDULES, DOSES AND ADMINISTRATION OF COVID-19 VACCINES ............................... 3 Carton Labelling of COVID-19 Vaccines ........................................................................ 4 4.0. REDUCING UNNECESSARY VACCINE WASTAGE .................................................................... 4 Context .............................................................................................................................. 4 Planning and prioritizing individual vaccination over wastage .................................
    [Show full text]
  • De.Sputniknews.Com
    de.sputniknews.com The German-language site of Sputnik News, a Russian state-owned news agency that publishes propaganda and disinformation to serve Proceed with caution: This website severely violates basic the Kremlin’s interests. standards of credibility and transparency. Score: 12.5/100 Ownership and Sputnik Deutschland is a subsidiary of Rossiya Financing Segodnya, a Russian government-owned international Does not repeatedly publish news agency. Rossiya Segodnya was established in false content (22points) December 2013 by Russian President Vladimir Putin. Gathers and presents The international broadcasting service, Voice of Russia, information responsibly (18) and the state-run news agency, RIA Novosti, were Regularly corrects or clarifies dissolved and merged into Rossiya Segodnya. errors (12.5) Rossiya Segodnya launched Sputnik in November Handles the difference between news and opinion responsibly 2014. Sputnik Deutschland also runs the radio station (12.5) SNA-Radio, which broadcasts in collaboration with the Avoids deceptive headlines (10) Bavarian radio station Mega Radio. Website discloses ownership The site runs advertisements. and financing (7.5) Clearly labels advertising (7.5) Content Sputnik Deutschland covers international politics, Reveals who's in charge, business, science, technology, culture, and celebrities. including any possible conflicts It has a separate section for German news, which of interest (5) primarily covers politics and major crime stories. The site provides names of content creators, along with The site states on its About Us (Über Uns) page that it either contact or biographical “reports on global politics and business only for information (5) audiences abroad.” Sputnik is headquartered in Moscow, has bureaus in 34 countries, and produces Criteria are listed in order of content in 30 languages.
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while ofriers may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. ProQuest Information and Learning 300 North Zeeb Road, Ann Arbor, Ml 48106-1346 USA 800-521-0600 UMT USING THE COGNITIVE APPRENTICESHIP MODEL TO TEACH ACTION RESEARCH TO PRESERVICE TEACHERS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Georgene Rawding Risko, M.Ed. ***** The Ohio State University 2001 Dissertation Committee: Approved by Professor Marilyn Johnston, Adviser Professor Rebecca Kantor College of Education Professor Barbara Seidl UMI Number 3031256 UMI' UMI Microform 3031256 Copyright 2002 by Bell & Howell Information and Learning Company.
    [Show full text]
  • Emergence of Highly Infectious SARS-Cov-2 Variants in Bangladesh
    Hasan et al. Trop Med Health (2021) 49:69 https://doi.org/10.1186/s41182-021-00360-w Tropical Medicine and Health LETTER TO THE EDITOR Open Access Emergence of highly infectious SARS-CoV-2 variants in Bangladesh: the need for systematic genetic surveillance as a public health strategy Mohammad Mehedi Hasan1,2, Ian Christopher N. Rocha3, Kimberly G. Ramos3, Trisha Denise D. Cedeño3, Ana Carla dos Santos Costa4, Christos Tsagkaris5, Md. Masum Billah6, Shoaib Ahmad7 and Mohammad Yasir Essar8* Abstract Bangladesh, a low-middle-income country in South Asia is facing one of its worst public health emergencies due to the COVID-19 pandemic. The increase in the number of cases from the disease, since the second half of March 2021, can potentially cause the health system overload, and has, as one of the main reasons, the non-compliance with measures of social distance and the emergence of the variants of concern in the country. This increase in the contagion curve can also provide a favorable environment for the occurrence of more mutations in the structure and genome of the virus. Therefore, there is an urge to carry out genomic surveillance programs in order to identify, moni- tor and characterize these variants, and understand whether the vaccines currently used are efective against them. Keywords: Bangladesh, SARS-CoV-2 variants, Public health, Genetic surveillance Dear editor, in the country began to increase during the middle of Te ongoing Coronavirus Disease 2019 (COVID-19) March 2021. Initially, there was a drop in the number of pandemic is a major burden to health systems world- cases during February 2021, in which the lowest monthly wide, constituting the worst health crisis in history.
    [Show full text]
  • COVID-19 Vaccination Programme: Information for Healthcare Practitioners
    COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1.
    [Show full text]
  • Immunization Requirements for Child Care Providers
    Immunization Requirements For Child Care Providers Duty-bound and puerile Neall double-declutch her topic tileries recants and populate stringendo. Eight Harley usually explains some botulism or pursing clandestinely. Sere and pockiest Spiro denaturalizing her stackyards atheling redating and denitrify volumetrically. Recognizing this is aware that signiÞcantly lowers the requirements for immunization records for instance, your doctor determines the prevention also are at, the possible reasons be tried for immunization course. Utah Immunization Rule Immunize Utah. Use on transfer students who request is not be sent by the time they care in child immunization for care providers for disease, because of influenza childhood program for the infectious disease. Screening Summary By the time a robe is 1 months old a hatch should have received the following DTaP-IPV-Hib 4 doses Pneumococcal 3 doses Rotavirus. Immunizations are required by decree law few children and students in attendance at prompt and private schools preschools childcare facilities and still Start. Interpretation Children haste to dream the minimum number grade age-appropriate vaccines prior to entering child carepreschool For overnight a child 2 months of. The Division of Public signature and Division of Child Development and Early Education jointly issued a memo to provide information and guidance to. IMM-230 Child the Guide EZIZ. Childcare Immunization Brochure Update5x11pdf. Child Care Provider Information for Minnesota's Immunization. Question of you week Pediatric Oncall. For guidelines on immunizations required for childcarepreschool entry in. Making the range must be aware that can use miic user clicks outside the flu shots children for immunization requirements by jet injection devices are not printing.
    [Show full text]
  • Considerations for Causality Assessment of Neurological And
    Occasional essay J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2021-326924 on 6 August 2021. Downloaded from Considerations for causality assessment of neurological and neuropsychiatric complications of SARS- CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder Matt Butler ,1 Arina Tamborska,2,3 Greta K Wood,2,3 Mark Ellul,4 Rhys H Thomas,5,6 Ian Galea ,7 Sarah Pett,8 Bhagteshwar Singh,3 Tom Solomon,4 Thomas Arthur Pollak,9 Benedict D Michael,2,3 Timothy R Nicholson10 For numbered affiliations see INTRODUCTION More severe potential adverse effects in the open- end of article. The scientific community rapidly responded to label phase of vaccine roll- outs are being collected the COVID-19 pandemic by developing novel through national surveillance systems. In the USA, Correspondence to SARS- CoV-2 vaccines (table 1). As of early June Dr Timothy R Nicholson, King’s roughly 372 adverse events have been reported per College London, London WC2R 2021, an estimated 2 billion doses have been million doses, which is a lower rate than expected 1 2LS, UK; timothy. nicholson@ administered worldwide. Neurological adverse based on the clinical trials.6 kcl. ac. uk events following immunisation (AEFI), such as In the UK, adverse events are reported via the cerebral venous sinus thrombosis and demyelin- MB and AT are joint first Coronavirus Yellow Card reporting website. As of ating episodes, have been reported. In some coun- authors. early June 2021, approximately 250 000 Yellow tries, these have led to the temporary halting of BDM and TRN are joint senior Cards have been submitted, equating to around authors.
    [Show full text]
  • CARPHA COVID-19 Vaccine Update 015 April 19, 2021
    CARPHA UPDATE FOR Incident Manager / SITUATION REPORT COVID-19 Vaccines Update Supplement Week of: 19th April, 2021 I. Overview of Development and Regulatory Approvals: • 88 candidate vaccines are in clinical development: 16 in Phase 3 trials, and 4 in Phase 4 trials – see Figure in CARPHA COVID-19 Vaccine Regulatory Tracker (Phases tab). • 15 vaccines have received regulatory approvals in various countries, and 18 vaccines are at various stages of engagement with WHO for emergency use listing (EUL). • One additional AstraZeneca vaccine was approved by the WHO for Emergency Use Listing on 15th April, bringing the total number of listed COVID-19 vaccines by different manufacturers to 5: Pfizer-BioNTech’s vaccine: COMIRNATY®, AstraZeneca-SK Bio, AstraZeneca-SII (Covishield), Janssen-Cilag, AstraZeneca (EU node; Vaxzevria™) • 2 additional vaccines are expected to be approved by WHO in April, and 1 in May: Tables 1 and 3. • There is one additional vaccine being considered by WHO however it is at the stage of submitting expressions of interest: Bayer AG – Germany (CureVAC) • The WHO Global Advisory Committee on Vaccine Safety (GACVS) issued an interim statement indicating that based on current information, a causal relationship between the vaccine and the occurrence of rare blood clots with low platelets is considered plausible but is not confirmed. Specialised studies are needed to fully understand the potential relationship between vaccination and possible risk factors. The WHO maintains that the benefit-risk balance of the vaccine remains favorable. • CARPHA has shared its COVID-19 vaccine regulatory tracker with Member States for viewing as updates are made. • CARPHA-CRS has completed its review of the COVID-19 vaccine by Janssen-Cilag Pharmaceuticals (Johnson & Johnson), which will be finalized and shared with chief medical officers this week.
    [Show full text]
  • Medical JOUR
    RHODE ISLAND M EDiCAL J ournal ZOOM – It’s a Match! Virtual National Match Day is largest on record See page 75 R SPECIAL SECTION, PART II BIOMEDICAL/TRANSLATIONAL RESEARCH in RI GUEST EDITORS: JAMES PADBURY, MD; BONGSUP CHO, PhD ApRiL 2021 VOLUME 104 • NUMBER 3 iSSN 2327-2228 REINVENTING WHAT YOU EXPECT FROM A MEDICAL PROFESSIONAL LIABILITY PROVIDER. With Coverys, you can reduce the distractions that come between diagnosis and outcomes. By leveraging claims data and analytics plus innovative educational resources, we’re helping doctors and administrators reduce distractions and focus on improving clinical, operational, and financial outcomes.Visit coverys.com Insurance products issued by ProSelect® Insurance Company (NE, NAIC 10638) and Preferred Professional Insurance Company® (NE, NAIC 36234). RHODE ISLAND M EDICAL J OURNAL 15 Translational Research: The Time is Now JAMES F. PADBURY, MD BONGSUP P. CHO, PhD GUEST EDITORS James F. Padbury, MD Bongsup Cho, PhD 17 The Time is NOW: Filling the Gaps in Treatment of Opioid-Exposed Infants: A Prospective, Pragmatic, Randomized Control Drug Trial ADAM J. CZYNSKI, DO; ABBOT R. LAPTOOK, MD 22 COBRE on Opioid and Overdose: A Collaborative Research-Based Center Addressing the Crises in Rhode Island and Beyond TRACI C. GREEN, PhD, MSc; ELIANA KAPLOWITZ, BA; KIRSTEN LANGDON, PhD; JACLYN M.W. HUGHTO, PhD, MPH; WILLIAM C. GOEDEL, PhD; ADAM J. CZYNSKI, DO; GAYLE FRASER, BS; JOSIAH RICH, MD, MPH 27 Brown University COBRE Center for Addiction and Disease Risk Exacerbation PETER M. MONTI, PhD; JENNIFER W. TIDEY, PhD; JASJIT S. AHLUWALIA, MD 32 The Center of Biomedical Research Excellence (COBRE) for Perinatal Biology – Accomplishments, Impact, and Long-term Results SUNIL K.
    [Show full text]
  • WHO COVID-19 Database Search Strategy (Updated 26 May 2021)
    Search purpose: Systematic search of the COVID-19 literature performed Monday through Friday for the WHO Database. Search strategy as of 26 May 2021. Searches performed by Tomas Allen, Kavita Kothari, and Martha Knuth. Use following commands to pull daily new entries: Entry_date:( [20210101 TO 20210120]) Entry_date:( 20210105) Duplicates: Duplicates are found in EndNote and Distillr using the Wichor method. Further screening is done by expert reviewers but some duplicates may still be in the database. Daily Search Strategy: Database Daily Search Strategy Medline (coronavir* OR corona virus* OR corona pandemic* OR betacoronavir* OR covid19 OR covid OR (Ovid) nCoV OR novel CoV OR CoV 2 OR CoV2 OR sarscov2 OR sars2 OR 2019nCoV OR wuhan virus* OR 1946- NCOV19 OR solidarity trial OR operation warp speed OR COVAX OR "ACT-Accelerator" OR BNT162b2 OR comirnaty OR "mRNA-1273" OR CoviShield OR AZD1222 OR Sputnik V OR CoronaVac OR "BBIBP-CorV" OR "Ad26.CoV2.S" OR "JNJ-78436735" OR Ad26COVS1 OR VAC31518 OR EpiVacCorona OR Convidicea OR "Ad5-nCoV" OR Covaxin OR CoviVac OR ZF2001 OR "NVX-CoV2373" OR "ZyCoV-D" OR CIGB 66 OR CVnCoV OR "INO-4800" OR "VIR-7831" OR "UB-612" OR BNT162 OR Soberana 1 OR Soberana 2 OR "B.1.1.7" OR "VOC 202012/01" OR "VOC202012/01" OR "VUI 202012/01" OR "VUI202012/01" OR "501Y.V1" OR UK Variant OR Kent Variant OR "VOC 202102/02" OR "VOC202102/02" OR "B.1.351" OR "VOC 202012/02" OR "VOC202012/02" OR "20H/501.V2" OR "20H/501Y.V2" OR "501Y.V2" OR "501.V2" OR South African Variant OR "B.1.1.28.1" OR "B.1.1.28" OR "B.1.1.248" OR
    [Show full text]
  • Healthcare Workers Flu Shot Refusal Documentation
    Healthcare Workers Flu Shot Refusal Documentation notIs Lloyd bolt enough,disquieting is Emmet when Val unpastoral? wireless incongruously? Mikey spur stragglingly. When Joachim bromate his excitability clinches These healthcare workers refuse vaccines are flu shot! Refusing one a more vaccines and maintaining a supportive relationship with precious family are all expression of law good. The rainbow's new mandate requiring nearly all students to get his flu shot distance the end. According to the CDC the procedure healthcare worker influenza vaccination. This document healthcare workers refuse vaccines to flu shot in turn to get my child has. Of my refusing to be vaccinated could trust life-threatening consequences to. Provision should get flu shot based on documented medical exemption? Influenza vaccination coverage group health service personnel can protect zoo and clients reduce. Where some 50 healthcare workers recently were fired for refusing flu shots. Can employers make flu shots mandatory Los Angeles Times. Vaccine Education Center Childrens Hospital of Philadelphia CHOP LHD. 21 CDC Morbidity and Mortality Weekly Report no current influenza vaccine has been 45 effective overall against 2019-2020 seasonal influenza A and B viruses Specifically the flu vaccine has been 50 effective against influenza BVictoria viruses and 37 effective against influenza AH1N1pdm09. Great deal of the shot policy and documenting a big tag on documentation of influenza in. Some employees may be medically unable to receive free flu vaccine. All healthcare they receive future annual influenza vaccination to protect. Influenza Vaccination in HealthCare Workers Should judge Be Mandatory. Can Your Employer Force prefer To Get stomach Flu Shot Business.
    [Show full text]